Editorial Commentary

Ketoconazole and Liver Injury: A Five-Year Update
David J. Greenblatt and Gerd Mikus

Articles

Bioequivalence Evaluation of Two Oral Formulations of Acetaminophen in Healthy Subjects: Results From a Randomized, Single-Blind, Crossover Study
Luis García Aguirre, Carlos Bohorquez Nassar, Isabel Ruiz Olmedo, Lara Dennie, and Araceli G. Medina Nolasco

Bioequivalence of Two Formulations of Gliclazide in a Randomized Crossover Study in Healthy Caucasian Subjects Under Fasting Conditions
Diana Ioana Pop, Monica Oroian, Sandeep Bhardwaj, Adriana Marcovici, Arshad Khuroo, Ravi Kochhar, and Laurian Vlase

Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion
Brett E. Houk, Christine W. Alvey, Ravi Visswanathan, Leonid Kirkovsky, Kyle T. Matschke, Emi Kimoto, Tim Ryder, R. Scott Obach, and Chandrasekar Durairaj

Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets
Kerri A. Schoedel, Michael Gillespie, Naama Levy-Cooperman, Megan J. Shram, and Laura Rabinovich-Guilatt

Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices
Ellen Q. Wang, Anna Plotka, Joanne Salageanu, Daniel Baltrukonis, Khurshid Mridha, Robert Frederich, and Beth E. Sullivan

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease
Ofer Spiegelstein, Dorit Mimrod, Laura Rabinovich, Eli Eyal, Craig Sprenger, Anna Elgart, Emil Samara, and Joel Morganroth

Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus
Stephen Wring, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, Michael Willett, and David Angulo

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers
Hiroko Ino, Akira Endo, Akira Wakamatsu, Hirofumi Ogura, Yotaro Numachi, and Stuart Kendrick

Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects
Hiroko Ino, Robert Wilson, Takumi Terao, Hirofumi Ogura, Harue Igarashi, Anthony Cahn, and Yotaro Numachi
Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
Fredric Cohen 87

Tramadol Hydrochloride at Steady State Lacks Clinically Relevant QTc Interval Increases in Healthy Adults
Joseph Massarella, Jay Ariyawansa, Jaya Natarajan, Stephan Francke, Thomas Murtaugh, Byron DeLemos, Subusola Vaughan, and Sergio Fonseca 95

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects
Elizabeth Bertran, Helen D. Berlie, Aaron Nixon, and Linda Jaber 119

A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15-mg Tylerdipine Tablet in Healthy Chinese Male Volunteers
Lu Wang, Lijun Xie, Sufeng Zhou, Yuanyuan Wang, Juan Chen, Yanli Zhou, Yun Liu, Hongwen Zhang, Mingxue Tao, Ning Ou, and Feng Shao 126
Editor-in-Chief:
David J. Greenblatt, Tufts University, USA

Managing Editor:
Elizabeth Marshall, Towson, MD

Editorial Board:
Joseph S. Bertino, Jr, Schenectady, NY; Bertino Consulting
Lawrence J. Botticelli, Cambridge, MA; Lipidion Therapeutics LLC
Michael H. Court, Pullman, WA; Washington State University
Hartmut Derendorf, Gainesville, FL; University of Florida College of Pharmacy
Michael J. Fossler, Chesterbrook, PA; Trevena, Inc.
Kenneth I. Kaitin, Boston, MA; Tufts University School of Medicine
Donald E. Mager, Buffalo, NY; University of Buffalo
John S. Markowitz, Gainesville, FL; University of Florida
Gerd Mikus, Heidelberg, Germany; University of Heidelberg
Diane R. Mould, Phoenixville, PA; Projections Research Inc.
Amin Rostami-Hodjegan, Manchester, United Kingdom; University of Manchester
Edward M. Sellers, Toronto, Ontario, Canada; University of Toronto and DL Global Partners, Inc.
Daniel S. Sitar, Winnipeg, Manitoba, Canada; University of Manitoba
Phil Skolnick, Bethesda, MD; National Institute on Drug Abuse
Karthik Venkatakrishnan, Cambridge, MA; Takeda Pharmaceuticals International Co.
Lisa L. von Moltke, Waltham, MA; Alkermes, Inc.

Darrell R. Abernethy (Food and Drug Administration), founding Editorial Board member, passed away in November 2017.
David A. Flockhart (University of Indiana School of Medicine), founding Editorial Board member, passed away in November 2015.

Aims and Scope: Clinical Pharmacology in Drug Development is an international, peer-reviewed, online publication focused on publishing high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects. Acceptance of a manuscript in Clinical Pharmacology in Drug Development will be determined by scientific rigor and technical soundness rather than perceived importance of the presented results. Thus, negative study results are explicitly not an obstacle for positive acceptance decisions.

Disclaimer: The Publisher, the American College of Clinical Pharmacology, and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the American College of Clinical Pharmacology, and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the American College of Clinical Pharmacology, and Editors of the products advertised.